Our Highly Experienced Executive Team has a Proven Track Record of Leadership, Global Registration and Lifecycle Management for Dozens of Biopharmaceutical Products.
Ms. Bhatt joined Achaogen as Chief Business Officer in 2017. Ms. Bhatt brings to Achaogen more than 20 years of experience in corporate development and strategy in the biopharmaceutical industry. Most recently, Ms. Bhatt held the position of Vice President, Corporate Development at Gilead Sciences where she was responsible for executing licenses, acquisitions and collaborations across all of Gilead’s therapeutic areas. While at Gilead, she also led long-term global commercial and strategic planning for Gilead’s antiviral and respiratory franchises. Before Gilead, Ms. Bhatt held corporate development and strategy roles at Eli Lilly and Maxygen. Ms. Bhatt earned a B.A. in Chemistry from Pomona College, an M.S. in Biomedical Sciences from the University of California at San Diego, and an M.B.A. from the Kellogg School of Management at Northwestern University.
Ms. Dorling joined Achaogen as Chief Commercial Officer in 2017. Prior to Achaogen, Ms. Dorling spent 14 years at Genentech and Roche where, as Vice President of Global Product Strategy, Breast Cancer at Roche/Genentech, she was responsible for developing and implementing global commercialization and lifecycle strategies for the Breast Cancer Franchise. Previously, as Vice President of the Lytics Franchise, Ms. Dorling lead hospital-focused Sales and Marketing teams that promoted Activase and Cathflo in the acute care setting. Ms. Dorling also had multiple roles with increasing responsibility in Market Analysis and Strategy in Ophthalmology, Oncology, and ultimately leading multiple functions with portfolio-wide responsibility. Prior to joining Genentech Ms. Dorling had several roles in Business Development at Altus Biologics, DNA Sciences, and Clontech Laboratories. Ms. Dorling has a Bachelor of Arts in Molecular and Cellular Biology from the University of California at Berkeley, a Master's in Science in Pharmacology and Cancer Biology from Duke University, and a Master's in Business Administration from the Haas School of Business at the University of California at Berkeley.
Dr. Swem was appointed Chief Scientific Officer in February 2017 and, prior to that, was the Vice President, Head of Research at Achaogen since 2015. Prior to this position, Dr. Swem spent just under two years as the Director of Achaogen’s Therapeutic Antibody Program, where he developed a state-of-the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases. Before joining Achaogen, Dr. Swem spent approximately four years as a Scientist in the Department of Infectious Disease at Genentech. During his tenure at Genentech, he developed the anti-influenza A program, the anti-influenza B program, and began a small molecule anti-bacterial program. Under his leadership, the anti-influenza teams established an innovative human B cell enrichment and cloning technique to discover rare functional antibodies. This work led to the discovery of two broadly neutralizing antibodies targeting influenza A and influenza B.Dr. Swem served as the research lead on the anti-influenza development teams, which successfully transitioned the anti-influenza A antibody through Phase 1 and Phase 2 clinical trials and the anti-influenza B antibody into early development. The combination of these two human antibodies could constitute a therapy to treat all serious influenza infections. Prior to working at Genentech, Dr. Swem completed his postdoctoral work with Dr. Bonnie Bassler at Princeton University, where he successfully carried out multiple high-throughput screens to identify small molecule inhibitors of bacterial virulence cascades. Dr. Swem received his Ph.D. in microbiology from Indiana University.